目的 觀察氣滯胃痛顆粒聯(lián)合莫沙必利治療反流性食管炎的臨床療效。方法 選取焦作市第五人民醫(yī)院于2016年1月—2017年2月收治的反流性食管炎患者116例，隨機(jī)分為對(duì)照組和治療組，每組各58例。對(duì)照組口服枸櫞酸莫沙必利分散片，5 mg/次，3次/d；治療組在對(duì)照組基礎(chǔ)上口服氣滯胃痛顆粒，5 g/次，3次/d。兩組均持續(xù)治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者血漿胃動(dòng)素（MOT）、血清胃泌素（GAS）、血清炎癥因子水平和疼痛程度。結(jié)果 治療后，對(duì)照組臨床有效率為79.31%，顯著低于治療組的93.10%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者M(jìn)OT、GAS含量顯著升高（P < 0.05），且治療組血漿MOT和血清GAS顯著高于對(duì)照組（P < 0.05）。治療后，兩組患者腫瘤壞死因子-α（TNF-α）、IL-6水平顯著低于治療前（P < 0.05），且治療組比對(duì)照組降低更顯著（P < 0.05）。治療后，兩組患者視覺(jué)模擬評(píng)分法（VAS）顯著降低（P < 0.05），且治療組VAS評(píng)分顯著低于對(duì)照組（P < 0.05）。結(jié)論 氣滯胃痛顆粒聯(lián)合莫沙必利可有效提高反流性食管炎患者血漿MOT和血清GAS，降低血清TNF-α和IL-6水平。

Objective To observe the clinical efficacy of Qizhi Weitong Granules combined with mosapride in treatment of reflux esophagitis. Methods Patients (116 cases) with reflux esophagitis in Jiaozuo Jiaozuo Fifth People's Hospital from January 2016 to February 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Mosapride Citrate Dispersible Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Qizhi Weitong Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 4 week. After treatment, the clinical efficacy was evaluated, and the plasma MOT levels, serum GAS levels, serum inflammatory factor levels, degree of pain in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.31%, which was significantly lower than 93.10% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the MOT and GAS levels in two groups were significantly increased (P < 0.05), and the MOT and GAS levels in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the TNF-α and IL-6 levels in two groups were significantly decreased (P < 0.05), and the serum inflammatory factor levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the VAS score in two groups was significantly decreased (P < 0.05), and the score in the treatment group was significantly lower than those in the control group (P < 0.05). Conclusion Qizhi Weitong Granules combined with mosapride in treatment of reflux esophagitis can effectively increase the plasma MOT and serum GAS levels, and reduce serum TNF-α and IL-6 levels.

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（201504022）